LTR Pharma has signed a national pharmacy distribution agreement with Symbion for its erectile dysfunction medication, Spontan.
The non-exclusive agreement, which commences on 01 Mar 2025, enables LTR Pharma to leverage Symbion's extensive network of over 3,900 pharmacies across the country, making use of its warehousing, inventory functions and distribution services.
LTA Pharma says the collaboration will play a vital role in supporting the early access scheme they will use and sets a new foundation for Spontan's commercial launch following the completion of the regulatory approval process.
The product is currently available for prescription to eligible patients under the Therapeutic Goods Administration (TGA) special access scheme.
Spontan utilises intranasal delivery technology of vardenafil HCL, a PDE5 inhibitor, allowing for rapid drug absorption and action within 10 minutes.
"Partnering with Symbion is a pivotal step in building our commercial infrastructure.
"Symbion's extensive distribution network and expertise will ensure seamless access to Spontan across Australia," said LTA Pharma Chairman Lee Rodne.
"This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA's early access program, and prepare for Spontan's anticipated commercial launch.
"Together, we are ensuring the highest standards of pharmaceutical handling and service delivery." KB
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jan 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jan 25
